
Novo Nordisk Surges 24.9% in 30 Days After Q1 Beat, Bets on AI Partners Over In-House R&D
Novo Nordisk reported a Q1 2026 earnings beat and posted a 24.9% stock gain over the past 30 days. The company simultaneously outsourced its Parkinson's cell therapy programs to AI-enabled partner Cellular Intelligence, signaling a deliberate pivot from vertical integration to platform leverage. The move aligns with a broader Big Pharma shift toward AI-native drug discovery infrastructure led by NVIDIA's BioNeMo platform.









